Interstitielle Nephritis

Interstitial nephritis

Der Internist volume 50, pages1111–1126(2009)Cite this article

Zusammenfassung

Die interstitielle Nephritis beschreibt entzündliche Krankheitsentitäten, die im Wesentlichen im tubulointerstitiellen Raum stattfinden. Auslöser für interstitielle Nephritiden sind Medikamente (z. B. Antibiotika, nichtsteroidale Antirheumatika, Protonenpumpenhemmer), Infektionen und Systemerkrankungen. Die Klinik reicht vom asymptomatischen Verlauf über Flankenschmerzen bis zum akuten Nierenversagen. Häufig kommt es zu charakteristischen, detektierbaren tubulären Partialfunktionsstörungen: tubuläre Proteinurie (α1-Mikroglobulin), Hyperphosphaturie mit Hypophosphatämie, Aminoazidurie, verminderte H+-Sekretion mit metabolischer Azidose mit inadäquat hohem Urin-pH-Wert, Glukosurie, Salzverlust. Bei der medikamentös induzierten Form ist das Weglassen des auslösenden Agens oberstes Prinzip, nach Infektionsausschluss hat sich die Gabe von Kortikosteroiden bewährt. In der Mehrzahl der Fälle mit akutem Verlauf ist mit einer günstigen Prognose zu rechnen, bei der chronischen Verlaufsform, bei der auch die Glomeruli betroffen sind, bedarf es aller supportiven Maßnahmen im Sinne der Behandlung der chronischen Niereninsuffizienz, um eine weitere Funktionsverschlechterung bis zur Entwicklung einer ESRD („end-stage renal disease“) abzuwenden.

Abstract

Drugs such as antibiotics, non-steroidal anti-inflammatory drugs and proton pump inhibitors, infections and systemic diseases can trigger interstitial nephritis. The clinical outcome varies from asymptomatic progression to acute kidney injury. Interstitial nephritis often leads to characteristic and detectable partial tubular disorders such as tubular proteinuria (α1-microglobulin), phosphaturia with hypophosphatemia, aminoaciduria, diminished H+ secretion with metabolic acidosis with inadequate high urinary pH, glucosuria and salt loss. The main principle of treatment is avoidance of the inducing agent. In addition corticosteroids have been proven usable after exclusion of an infection so that a good prognosis can be expected for acute nephritis in the majority of cases. In chronic forms the interstitial nephritis involves the glomeruli as well as potentially resulting in end-stage renal failure in the long run. Supportive therapies are then required in the sense of chronic renal failure in order to prevent further functional loss up to end-stage renal disease.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. 1.

    Baker RJ, Pusey CD (2004) The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 19(1):8–11

    PubMed  Article  Google Scholar 

  2. 2.

    Michel DM, Kelly CJ (1998) Acute interstitial nephritis. J Am Soc Nephrol 9(3):506–515

    PubMed  CAS  Google Scholar 

  3. 3.

    Clarkson MR et al (2004) Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 19(11):2778–2783

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Nolan CR 3rd, Anger MS, Kelleher SP (1986) Eosinophiluria – a new method of detection and definition of the clinical spectrum. N Engl J Med 315(24):1516–1519

    PubMed  Google Scholar 

  5. 5.

    Rossert J (2001) Drug-induced acute interstitial nephritis. Kidney Int 60(2):804–817

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Galpin JE et al (1978) Acute interstitial nephritis due to methicillin. Am J Med 65(5):756–765

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Nolan CM, Abernathy RS (1977) Nephropathy associated with methicillin therapy. Prevalence and determinants in patients with staphylococcal bacteremia. Arch Intern Med 137(8):997–1000

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Ra A, Tobe SW (2004) Acute interstitial nephritis due to pantoprazole. Ann Pharmacother 38(1):41–45

    PubMed  Article  Google Scholar 

  9. 9.

    Ricketson J et al (2009) Acute allergic interstitial nephritis after use of pantoprazole. CMAJ 180(5):535–538

    PubMed  Google Scholar 

  10. 10.

    Sierra F et al (2007) Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26(4):545–553

    PubMed  CAS  Article  Google Scholar 

  11. 11.

    Abdul Ghani R et al (2009) Acute renal failure following the use of rosiglitazone in a chronic kidney disease patient. Singapore Med J 50(1):e32–e34

    Google Scholar 

  12. 12.

    Gurevich F, Perazella MA (2009) Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 122(4):322–328

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Patel H, Barr A, Jeejeebhoy KN (2009) Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 23(3):170–176

    PubMed  CAS  Google Scholar 

  14. 14.

    Bennett WM, DeBroe ME (1989) Analgesic nephropathy–a preventable renal disease. N Engl J Med 320(19):1269–1271

    PubMed  CAS  Google Scholar 

  15. 15.

    Pinter I et al (2004) Analgesic nephropathy in Hungary: the HANS study. Nephrol Dial Transplant 19(4):840–843

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Perneger TV, Whelton PK, Klag MJ (1994) Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331(25):1675–1679

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Curhan GC et al (2004) Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 164(14):1519–1524

    PubMed  Article  Google Scholar 

  18. 18.

    Boton R, Gaviria M, Batlle DC (1987) Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 10(5):329–345

    PubMed  CAS  Google Scholar 

  19. 19.

    Presne C et al (2003) Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 64(2):585–592

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Waller DG, Edwards JG, Papasthatis-Papayanni S (1988) A longitudinal assessment of renal function during treatment with lithium. Q J Med 68(255):553–558

    PubMed  CAS  Google Scholar 

  21. 21.

    Farres MTet al (2003) Chronic lithium nephropathy: MR imaging for diagnosis. Radiology 229(2):570–574

    PubMed  Article  Google Scholar 

  22. 22.

    Markowitz GS et al (2000) Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 11(8):1439–1448

    PubMed  CAS  Google Scholar 

  23. 23.

    Yang CW (2007) Leptospirosis renal disease: understanding the initiation by Toll-like receptors. Kidney Int 72(8):918–925

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Muranyi W et al (2005) Hantavirus infection. J Am Soc Nephrol 16(12):3669–3679

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Poux JM et al (1992) Hypokalemic quadriplegia and respiratory arrest revealing primary Sjogren’s syndrome. Clin Nephrol 37(4):189–191

    PubMed  CAS  Google Scholar 

  26. 26.

    Shearn MA, Tu WH (1965) Nephrogenic diabetic insipidus and other defects of renal tubular function in sjoergren’s syndrome. Am J Med 39:312–318

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Bastani B et al (1995) Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sjogren’s syndrome. Nephrol Dial Transplant 10(6):908–909

    PubMed  CAS  Google Scholar 

  28. 28.

    Stolt A et al (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84(Pt 6):1499–1504

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Shah KV (2000) Human polyomavirus BKV and renal disease. Nephrol Dial Transplant 15(6):754–755

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Hirsch HH et al (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347(7):488–496

    PubMed  Article  Google Scholar 

  31. 31.

    Saad ER et al (2008) Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 85(6):850–854

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Kuypers DR et al (2005) Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 5(8):1997–2004

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Blanckaert K, De Vriese AS (2006) Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. Nephrol Dial Transplant 21(12):3364–3367

    PubMed  Article  Google Scholar 

  34. 34.

    Asberg A et al (2007) Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7(9):2106–2113

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Farrugia E, Schwab TR (1992) Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 67(9):879–890

    PubMed  CAS  Google Scholar 

  36. 36.

    Dobrin RS, Vernier RL, Fish AL (1975) Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome. Am J Med 59(3):325–333

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Abed L et al (2008) Presence of autoantibodies against tubular and uveal cells in a patient with tubulointerstitial nephritis and uveitis (TINU) syndrome. Nephrol Dial Transplant 23(4):1452–1455

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Sessa A et al (2000) Acute renal failure due to idiopathic tubulo-intestinal nephritis and uveitis: „TINU syndrome“. Case report and review of the literature. J Nephrol 13(5):377–380

    PubMed  CAS  Google Scholar 

  39. 39.

    Simon AH, Alves-Filho G, Ribeiro-Alves MA (1996) Acute tubulointerstitial nephritis and uveitis with antineutrophil cytoplasmic antibody. Am J Kidney Dis 28(1):124–127

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Djukanovic L et al (2002) Epidemiology of end-stage renal disease and current status of hemodialysis in Yugoslavia. Int J Artif Organs 25(9):852–859

    PubMed  CAS  Google Scholar 

  41. 41.

    Cosyns JP et al (1994) Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 45(6):1680–1688

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Bukvic D et al (2005) Balkan endemic nephropathy is still present in the Kolubara region, Serbia. Ren Fail 27(5):565–569

    PubMed  Article  Google Scholar 

  43. 43.

    Petronic VJ et al (1991) Balkan endemic nephropathy and papillary transitional cell tumors of the renal pelvis and ureters. Kidney Int Suppl 34:S77–S79

    PubMed  CAS  Google Scholar 

  44. 44.

    Stewart JH et al (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14(1):197–207

    PubMed  Article  Google Scholar 

  45. 45.

    Appel GB (2008) The treatment of acute interstitial nephritis: More data at last. Kidney Int 73(8):905–957

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Buysen JG et al (1990) Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 5(2):94–99

    PubMed  CAS  Google Scholar 

  47. 47.

    Gonzalez E et al (2008) Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73(8):940–946

    PubMed  Article  CAS  Google Scholar 

  48. 48.

    Preddie DC et al (2006) Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol 1(4):718–722

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Mayer C et al (2008) Isolated renal relapse of sarcoidosis under low-dose glucocorticoid therapy. J Gen Intern Med 23(6):879–882

    PubMed  Article  Google Scholar 

  50. 50.

    Strutz FM (2009) EMT and proteinuria as progression factors. Kidney Int 75(5):475–481

    PubMed  Article  CAS  Google Scholar 

Download references

Interessenskonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Affiliations

  1. Medizinische Klinik und Poliklinik für Endokrinologie und Nephrologie, Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig, A.ö.R., Leipzig, Liebigstr. 20, 04159, Leipzig, Deutschland

    J. Halbritter, C. Mayer, F.M. Rasche & Prof. Dr. T.H. Lindner

  2. Nephropathologische Abteilung, Universitätsklinikum Erlangen, Erlangen, Deutschland

    K. Amann

Authors
  1. J. Halbritter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F.M. Rasche
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Amann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. T.H. Lindner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prof. Dr. T.H. Lindner.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Halbritter, J., Mayer, C., Rasche, F. et al. Interstitielle Nephritis. Internist 50, 1111–1126 (2009). https://doi.org/10.1007/s00108-009-2463-2

Download citation

Schlüsselwörter

  • Interstitielle Nephritis
  • Tubulointerstitielle Nephritis und Uveitis (TINU)
  • Analgetikanephropathie
  • Balkan-Nephritis
  • Lithium-Nephropathie

Keywords

  • Interstitial nephritis
  • Tubulointerstitial nephritis and uveitis (TINU)
  • Analgesic nephropathy
  • Balkan-endemic nephropathy
  • Lithium kidney disease